"label","text","name","description","instanceType","id","uuid:ID"
"","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","OBJ1","Main objective","OBJECTIVE","Objective_1","1d3670ba-e36c-43ec-82c3-bc19de6e7015"
"","To document the safety profile of the xanomeline TTS.","OBJ2","Safety","OBJECTIVE","Objective_2","e7fdbcf4-9755-4777-b3b3-f86a5ed368ba"
"","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","OBJ3","Behaviour","OBJECTIVE","Objective_3","acb7a1fd-b1c8-4c1b-8f7e-98fdb05cdec6"
